Radiosurgery for Glioblastoma Multiforme
- Conditions
- Glioblastoma Multiforme
- Interventions
- Procedure: CyberKnife
- Registration Number
- NCT00456612
- Lead Sponsor
- Beth Israel Deaconess Medical Center
- Brief Summary
Conventional radiation for 6 weeks is not well tolerated by the elderly. Shorter courses (over 3-5 weeks) of radiation have been shown to be equivalent in outcome the elderly- particularly in patients who are generally in poor performance status (KPS\<70). Fractionated Cyberknife Radiosurgery can deliver equivalent doses in 5 treatments providing the same tumor control in a much shorter and tolerable schedule improving their quality of their short life.
To assess the tolerability of Cyberknife Radiosurgery for High Grade Gliomas in Elderly with poor performance status.
Secondary:
Assessment of local control rate, progression free survival, overall survival, quality of life and toxicity and steroid dependence in this population with this regime.
- Detailed Description
Conventional radiation for 6 weeks is not well tolerated by the elderly. Shorter courses (over 3-5 weeks) of radiation have been shown to be equivalent in outcome the elderly- particularly in patients who are generally in poor performance status (KPS\<70). Fractionated Cyberknife Radiosurgery can deliver equivalent doses in 5 treatments providing the same tumor control in a much shorter and tolerable schedule improving their quality of their short life.
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 4
-
Histopathologically confirmed newly diagnosed glioblastoma multiforme or Anaplastic Glioma (WHO Grade III) by surgical excision or biopsy.
-
Patient must recover from the effects of surgery, post-operative infection, or other complications.
-
Therapy should start within 5 weeks of surgery
-
Must have an estimated survival of > 8 weeks.
-
KPS < 70.
-
Age > 65 years.
-
Must have a pre- and post operative contrast enhanced MRI scans
-
Laboratory values within the following limits: ANC (absolute neutrophil count) >/= 1500 cell/ul Platelets >/= 100x 10(3)/ul, Hemoglobin >/= 9g/dl, Serum Creatinine ≤ 1.5mg/dl., Serum total Bilirubin </= 1.5 x upper limit of normal (ULN), SGOT/SGPT </= 2.5x ULN, Albumin >/= 3g/dl.
-
Histology grade less than Anaplastic Glioma ( WHO Grade III).
-
Recurrent malignant glioma.
-
Tumor involving the Brain stem.
-
Any detected tumor foci beyond the cranial vault.
-
Major medical or psychiatric illness, which in the investigator's opinion will prevent administration or completion of the protocol therapy.
-
Prior malignancies, except for non-melanomatous skin cancers, or carcinoma in situ of uterus, cervix or bladder, unless disease free for > 5 years.
-
Prior chemotherapy for the current disease.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Cyberknife CyberKnife Radiosurgery to enhancing high grade glioma in 5 fractions with escalating doses.
- Primary Outcome Measures
Name Time Method The Percent Progression -Free Survival at 6 Months Will be Tabulated 6 months Progression Free Survival consent to prgression or death
- Secondary Outcome Measures
Name Time Method Response, Median Time to Tumor Progression,Overall Survival, Percent Overall Survival at 1 Year Will be Tabulated. 1year
Trial Locations
- Locations (1)
Beth Israel Deaconess Medical Center
🇺🇸Boston, Massachusetts, United States